Pediatric multiple sclerosis (MS) comprises 2-5% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested that a growing number of children suffer from disease which is resistant to treatment with these therapies. Natalizumab is a therapy which, although associated with a 1 : 1000 risk for progressive multifocal leukoencephalopathy (PML), has been shown to be well tolerated in the adult population and may lead to disease remission in adults with highly active disease. Reports of use of this therapy in the pediatric population with highly active disease have been published. This paper reviews current experience with the use of natalizumab in the pediatric MS population, with attention to potential risks and possible long-term outcomes in this population.
Angelini, L., Pietrogrande, M.C., Delle Piane, M.R., Zibordi, F., Cinque, P., Maccagnano, C. et al. (2001) Progressive multifocal leukoencephalopathy in a child with hyperimmunoglobulin E recurrent infection syndrome and review of the literature. Neuropediatrics32: 250-255.
2.
Archelos, J., Pervitali, S. and Hartung, H. ( 1999) The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci22: 30-38.
3.
Balcer, L.J., Galetta, S.L., Calabresi, P.A., Confavreux, C., Giovannoni, G., Havrdova, E. et al. (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology68: 1299-1304.
4.
Banwell, B., Reder, A.T., Krupp, L., Tenembaum, S., Eraksoy, M., Alexey, B. et al. (2006) Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology66: 472-476.
5.
Berger, J.R., Scott, G., Albrecht, J., Belman, A.L., Tornatore, C. and Major, E.O. ( 1992) Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS6: 837-841.
6.
Bezabeh, S., Flowers, C.M., Kortepeter, C. and Avigan, M.(2010) Clinically significant liver injury in patients treated with natalizumab . Aliment Pharmacol Ther31: 1028-1035.
7.
Borriello, G., Prosperini, L., Luchetti, A. and Pozzilli, C.(2009) Natalizumab treatment in pediatric multiple sclerosis: a case report . Eur J Paediatr Neurol13: 67-71.
8.
Calabresi, P.A., Giovannoni, G., Confavreux, C., Galetta, S.L., Havrdova, E., Hutchinson, M. et al. (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology69: 1391-1403.
9.
Chen, Y., Bord, E., Tompkins, T., Miller, J., Tan, C.S., Kinkel, R.P. et al. (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med361: 1067-1074.
10.
Clifford, D.B., De Luca, A., Simpson, D.M., Arendt, G., Giovannoni, G. and Nath, A.(2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol9: 438-446.
11.
Coisne, C., Mao, W. and Engelhardt, B.(2009) Cutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol182: 5909-5913.
12.
Ghezzi, A., Amato, M.P., Annovazzi, P., Capobianco, M., Gallo, P., La Mantia, L. et al. (2009) Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience . Neurol Sci30: 193-199.
13.
Ghezzi, A., Amato, M.P., Capobianco, M., Gallo, P., Marrosu, G., Martinelli, V. et al. (2005) Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler11: 420-424.
14.
Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C.H. et al. (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study . Lancet Neurol8: 254-260.
15.
Hellwig, K., Schimrigk, S., Fischer, M., Haghikia, A., Muller, T., Chan, A. et al. (2008) Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol65: 656-658.
16.
Huppke, P., Stark, W., Zurcher, C., Huppke, B., Bruck, W. and Gartner, J. ( 2008) Natalizumab use in pediatric multiple sclerosis. Arch Neurol65: 1655-1658.
17.
Hutchinson, M., Kappos, L., Calabresi, P.A., Confavreux, C., Giovannoni, G., Galetta, S.L. et al. (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol256: 405-415.
18.
Hyams, J.S., Wilson, D.C., Thomas, A., Heuschkel, R., Mitton, S., Mitchell, B. et al. (2007) Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr44: 185-191.
19.
Katz, D.A., Berger, J.R., Hamilton, B., Major, E.O. and Post, M.J. ( 1994) Progressive multifocal leukoencephalopathy complicating Wiskott-Aldrich syndrome. Report of a case and review of the literature of progressive multifocal leukoencephalopathy with other inherited immunodeficiency states. Arch Neurol51: 422-426.
20.
Khatri, B.O., Man, S., Giovannoni, G., Koo, A.P., Lee, J.C., Tucky, B. et al. (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology72: 402-409.
21.
Kleinschmidt-DeMasters, B. and Tyler, K. ( 2005) Progressive multifocal leukoencphalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med353: 369-374.
22.
Knowles, W.A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D.W. et al. (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol71: 115-123.
23.
Kornek, B., Bernert, G., Balassy, C., Geldner, J., Prayer, D. and Feucht, M. ( 2003) Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics34: 120-126.
24.
Krumbholz, M., Pellkofer, H., Gold, R., Hoffmann, L.A., Hohlfeld, R. and Kumpfel, T. ( 2007) Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol64: 1331-1333.
25.
Langer-Gould, A., Atlas, S., Green, A.J., Bollen, A.W. and Pelletier, D. ( 2005) Progressive multifocal encephalopathy in a patient treated with natalizumab. N Engl J Med353: 375-381.
26.
Linda, H., von Heijne, A., Major, E.O., Ryschkewitsch, C., Berg, J., Olsson, T. et al. (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med361: 1081-1087.
27.
Liptai, Z., Papp, E., Barsi, P., Mihaly, I., Szalai, E., Csomor, J. et al. (2007) Progressive multifocal leukoencephalopathy in an HIV-infected child. Neuropediatrics38: 32-35.
Mikaeloff, Y., Caridade, G., Tardieu, M. and Suissa, S. ( 2008) Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol12: 205-209.
30.
Mikaeloff, Y., Moreau, T., Debouverie, M., Pelletier, J., Lebrun, C., Gout, O. et al. (2001) Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr139: 443-446.
31.
Miller, D.H., Soon, D., Fernando, K.T., MacManus, D.G., Barker, G.J., Yousry, T.A. et al. (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology68: 1390-1401.
32.
Nuttall, J.J., Wilmshurst, J.M., Ndondo, A.P., Yeats, J., Corcoran, C., Hussey, G.D. et al. (2004) Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome. Pediatr Infect Dis J23: 683-685.
33.
Oturai, A.B., Koch-Henriksen, N., Petersen, T., Jensen, P.E., Sellebjerg, F. and Sorensen, P.S.(2009) Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol16: 420-423.
34.
Pohl, D., Rostasy, K., Gartner, J. and Hanefeld, F. ( 2005) Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology64: 888-890.
35.
Pohl, D., Waubant, E., Banwell, B., Chabas, D., Chitnis, T., Weinstock-Guttman, B. et al. (2007) Treatment of pediatric multiple sclerosis and variants. Neurology68(16 Suppl 2): S54-S65.
36.
Polman, C.H., O’Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med354: 899-910.
37.
Polo, C., Perez, J.L., Mielnichuck, A., Fedele, C.G., Niubo, J. and Tenorio, A. ( 2004) Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect10: 640-644.
38.
Putzki, N., Yaldizli, O., Maurer, M., Cursiefen, S., Kuckert, S., Klawe, C. et al. (2010) Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries . Eur J Neurol17: 31-37.
39.
Radue, E.W., Stuart, W.H., Calabresi, P.A., Confavreux, C., Galetta, S.L., Rudick, R.A. et al. (2010) Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci292: 28-35.
40.
Rudick, R.A., Stuart, W.H., Calabresi, P.A., Confavreux, C., Galetta, S.L., Radue, E.W. et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med354: 911-923.
41.
Schweikert, A., Kremer, M., Ringel, F., Liebig, T., Duyster, J., Stüve, O. et al. (2009) Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol66: 403-406.
42.
Singer, C., Berger, J.R., Bowen, B.C., Bruce, J.H. and Weiner, W.J. ( 1993) Akinetic-rigid syndrome in a 13-year-old girl with HIV-related progressive multifocal leukoencephalopathy. Mov Disord8: 113-116.
43.
Stoner, G.L., Walker, D.L. and Webster, H.D. ( 1988) Age distribution of progressive multifocal leukoencephalopathy . Acta Neurol Scand78: 307-312.
44.
Stüve, O., Cravens, P.D., Frohman, E.M., Phillips, J.T., Remington, G.M., von Geldern, G. et al. (2009) Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology72: 396-401.
45.
VanAssche, G., Ranst, M.V., Sciot, R., Dubois, B., Vermeire, S., Noman, M. et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med353: 362-368.
46.
Vellinga, M.M., Castelijns, J.A., Barkhof, F., Uitdehaag, B.M. and Polman, C.H. ( 2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology70: 1150-1151.
47.
Wenning, W., Haghikia, A., Laubenberger, J., Clifford, D.B., Behrens, P.F., Chan, A. et al. (2009) Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med361: 1075-1080.
48.
Yednock, T.A., Cannon, C., Fritz, L.C., Sanchez-Madrid, F., Steinman, L. and Karin, N. ( 1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature356: 63-66.
49.
Yeh, E., Krupp, L., Kuntz, N., Ness, J., Chabas-Chanzon, D., Chitnis, T. et al. (2010) Use of natalizumab in pediatric MS patients: a pediatric network experience. Neurology74(9 Suppl 2): A100.
50.
Yeh, E., Krupp, L., Ness, J., Chabas, D., Belman, A., Waubant, E. et al. (2009) Breakthrough disease in pediatric MS patients: a pediatric network experience. Annual Meeting of the American Academy of Neurology, Seattle, WA.
51.
Yousry, T.A., Major, E.O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J. et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med354: 924-933.
